WO2021143954A3 - 一种氟伐替尼或其甲磺酸盐的晶型及其制备方法 - Google Patents
一种氟伐替尼或其甲磺酸盐的晶型及其制备方法 Download PDFInfo
- Publication number
- WO2021143954A3 WO2021143954A3 PCT/CN2021/081023 CN2021081023W WO2021143954A3 WO 2021143954 A3 WO2021143954 A3 WO 2021143954A3 CN 2021081023 W CN2021081023 W CN 2021081023W WO 2021143954 A3 WO2021143954 A3 WO 2021143954A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluvatinib
- crystalline form
- methanesulfonate
- preparation
- method therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
一种氟伐替尼或其甲磺酸盐的晶型及其制备方法,所述氟伐替尼的晶型I具有图1所示的特征衍射峰,所述氟伐替尼甲磺酸盐的晶型为多晶现象,具有晶型I-VII七种晶型,其中晶型III具有图9所不的特征衍射峰,这些晶型适应氣伐替尼甲横酸盐的制剂的制造过程。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21741704.7A EP4092014A4 (en) | 2020-01-19 | 2021-03-16 | CRYSTALLINE FORM OF FLUVATINIB OR FLUVATINIB METHANESULFONATE AND METHOD OF MANUFACTURE THEREOF |
JP2022543726A JP2023512621A (ja) | 2020-01-19 | 2021-03-16 | フルバチニブ又はそのメタンスルホン酸塩の結晶形およびその製造方法 |
US17/793,406 US20230106064A1 (en) | 2020-01-19 | 2021-03-16 | Crystalline form of fluvatinib or fluvatinib methanesulfonate and preparation method therefor |
JP2024040363A JP2024073574A (ja) | 2020-01-19 | 2024-03-14 | フルバチニブ又はそのメタンスルホン酸塩の結晶形およびその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010063033.6 | 2020-01-19 | ||
CN202010063033 | 2020-01-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021143954A2 WO2021143954A2 (zh) | 2021-07-22 |
WO2021143954A3 true WO2021143954A3 (zh) | 2021-08-26 |
Family
ID=76810909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/081023 WO2021143954A2 (zh) | 2020-01-19 | 2021-03-16 | 一种氟伐替尼或其甲磺酸盐的晶型及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230106064A1 (zh) |
EP (1) | EP4092014A4 (zh) |
JP (2) | JP2023512621A (zh) |
CN (2) | CN113135853A (zh) |
WO (1) | WO2021143954A2 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113480479B (zh) * | 2021-08-12 | 2022-08-02 | 上海爱博医药科技有限公司 | 脲类多靶点酪氨酸激酶抑制剂及其医药应用 |
CN115215799B (zh) * | 2022-08-12 | 2024-05-31 | 上海爱博医药科技有限公司 | 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018196687A1 (zh) * | 2017-04-25 | 2018-11-01 | 苏州科睿思制药有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
CN109134365A (zh) * | 2017-09-28 | 2019-01-04 | 南京明德新药研发股份有限公司 | 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用 |
US20190218184A1 (en) * | 2016-06-08 | 2019-07-18 | Crystal Pharmatech Co., Ltd | Novel Crystalline Form of Lenvantinib Mesylate and Process of Preparation Thereof |
WO2020187188A1 (zh) * | 2019-03-15 | 2020-09-24 | 南京明德新药研发有限公司 | 喹啉衍生物及免疫调节剂联合在制备抗肿瘤药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016184436A1 (zh) * | 2015-05-21 | 2016-11-24 | 苏州晶云药物科技有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
EP3299360A1 (en) * | 2016-09-21 | 2018-03-28 | INDENA S.p.A. | Crystal forms of lenvatinib |
CN110023288B (zh) * | 2016-09-30 | 2022-10-28 | 广东众生睿创生物科技有限公司 | 酪氨酸激酶抑制剂的晶型、盐型以及制备方法 |
-
2021
- 2021-01-18 CN CN202110060334.8A patent/CN113135853A/zh active Pending
- 2021-01-18 CN CN202410110265.0A patent/CN117945999A/zh active Pending
- 2021-03-16 EP EP21741704.7A patent/EP4092014A4/en active Pending
- 2021-03-16 US US17/793,406 patent/US20230106064A1/en active Pending
- 2021-03-16 WO PCT/CN2021/081023 patent/WO2021143954A2/zh active Application Filing
- 2021-03-16 JP JP2022543726A patent/JP2023512621A/ja active Pending
-
2024
- 2024-03-14 JP JP2024040363A patent/JP2024073574A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190218184A1 (en) * | 2016-06-08 | 2019-07-18 | Crystal Pharmatech Co., Ltd | Novel Crystalline Form of Lenvantinib Mesylate and Process of Preparation Thereof |
WO2018196687A1 (zh) * | 2017-04-25 | 2018-11-01 | 苏州科睿思制药有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
CN109134365A (zh) * | 2017-09-28 | 2019-01-04 | 南京明德新药研发股份有限公司 | 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用 |
WO2020187188A1 (zh) * | 2019-03-15 | 2020-09-24 | 南京明德新药研发有限公司 | 喹啉衍生物及免疫调节剂联合在制备抗肿瘤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP4092014A2 (en) | 2022-11-23 |
WO2021143954A2 (zh) | 2021-07-22 |
US20230106064A1 (en) | 2023-04-06 |
CN113135853A (zh) | 2021-07-20 |
EP4092014A4 (en) | 2023-08-16 |
JP2023512621A (ja) | 2023-03-28 |
CN117945999A (zh) | 2024-04-30 |
JP2024073574A (ja) | 2024-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021143954A3 (zh) | 一种氟伐替尼或其甲磺酸盐的晶型及其制备方法 | |
WO2008129490A3 (en) | Process for the production of a grain oriented magnetic strip | |
WO2005044791A3 (de) | 2-halogen-6-alkyl-phenyl-substituierte tetramsäure-derivate | |
WO2003054189A3 (de) | Verfahren zur transformation von pflanzlichen plastiden | |
WO2008130312A8 (en) | A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 | |
WO2008125983A3 (en) | Methods of increasing plant growth | |
WO2007030165A3 (en) | Zirconium strip meterial and process for making same | |
WO2018140934A8 (en) | Compositions and methods for hemoglobin production | |
WO2011098505A3 (de) | Kosmetische zubereitung mit einem gehalt an acylarginaten | |
WO2008140641A3 (en) | Pure paliperidone and processes for preparing thereof | |
WO2007012626A3 (de) | Neues verfahren zur herstellung von tiotropiumsalzen | |
WO2004018695A3 (de) | Verfahren zur herstellung von ketocarotinoiden in früchten von pflanzen | |
WO2019103834A3 (en) | Apparatus for manufacturing composite airfoils | |
WO2018012941A3 (ko) | 가스발생량이 낮은 류코노스톡 메센테로이드 cjlm119 균주 및 이를 이용한 김치의 제조방법 | |
EP3950109A4 (en) | METHODS OF PREPARATION OF GROUP 14 ELEMENTS DOped NANODIAMONDS AND METHODS OF PURIFICATION THEREOF | |
WO2021046422A3 (en) | Optimizing volatile entourages in dry flowering plant mixtures | |
WO2009039330A3 (en) | Compositions and methods for altering the morphology of plants | |
WO2007073937A3 (en) | Process for preparing crystalline forms of orlistat | |
WO2022026613A3 (en) | Methods and compositions for altering secondary metabolites in plants | |
EP4242335A4 (en) | METHOD FOR MANUFACTURING ALLOY ELEMENT, ALLOY ELEMENT AND PRODUCT USING ALLOY ELEMENT | |
WO2021086145A3 (ko) | 알룰로스를 포함하는 떡 및 이의 제조방법 | |
WO2008094617A3 (en) | Crystalline forms of deferasirox | |
EP4052771A4 (en) | METHOD FOR PRODUCING A CRYSTALLIZED PRODUCT CONTAINING REBAUDIOSIDE-D AND CRYSTALLIZED PRODUCT CONTAINING REBAUDIOSIDE-D | |
EP3936259A4 (en) | ADDITIVELY MANUFACTURED ARTICLE COMPRISING AN NI-BASED ALLOY ELEMENT, METHOD FOR MAKING AN NI-BASED ALLOY ELEMENT, AND PRODUCT USING AN NI-BASED ALLOY ELEMENT | |
EP4050133A4 (en) | METHOD OF MAKING A GALLIUM PRECURSOR AND METHOD OF MAKING A LAYERED PRODUCT USING THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21741704 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2022543726 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021741704 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |